10 results
6-K
EX-99.1
GLPG
Galapagos NV
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
that the company’s strong fundamentals will drive future growth as we continue to innovate and bring transformational medicines to patients,” added Bart Filius
6-K
EX-99.1
GLPG
Galapagos NV
10 Nov 20
Current report (foreign)
6:05am
to innovate in the inflammation space, with multiple, distinct mechanism of action approaches to bringing new therapy options to patients. GLPG3667 is an oral
6-K
EX-99.1
GLPG
Galapagos NV
7 Feb 19
Evotec and Galapagos enter into collaboration in the field of fibrosis
8:09am
and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established
6-K
EX-99.1
GLPG
Galapagos NV
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
by reshaping the way we innovate and operate. This strategy provides a clear path forward based on three key pillars. First, we will shift from novel target
6-K
EX-99.2
GLPG
Galapagos NV
6 May 22
Current report (foreign)
5:18pm
increasing infection rates of COVID-19 mainly due to the spread of the highly infectious Omicron-variant, we continue to innovate to accommodate
6-K
EX-99.2
eesv86uqdx1xwrk6
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.2
8brxw ldqs04sgb
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.2
xohq1ik1
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
- Prev
- 1
- Next